Ocuphire Pharma to Present at the Aegis Virtual Conference
Ocuphire Pharma to Present at the Aegis Virtual Conference
Ocuphire Pharma to Present at the Aegis Virtual Conference
Ocuphire Pharma 將在 Aegis 虛擬會議上發表演講
Download as PDF May 03, 2024
以 PDF 格式下載 2024 年 5 月 3 日
FARMINGTON HILLS, Mich., May 03, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders, today announced that George Magrath, M.D. M.B.A., M.S., Chief Executive Officer of Ocuphire, will present a company overview at the Aegis Virtual Conference being held May 7-9, 2024. Company management will also be participating in one-on-one meetings throughout the conference.
密歇根州法明頓希爾斯，2024年5月3日（GLOBE NEWSWIRE）——專注於開發治療視網膜和屈光眼疾病的新療法的臨床階段生物製藥公司Ocuphire Pharma, Inc.（納斯達克股票代碼：OCUP）今天宣佈，Ocuphire首席執行官MBA、M.S. George Magrath將發表一份報告 2024 年 5 月 7 日至 9 日舉行的 Aegis 虛擬會議上的公司概況。公司管理層還將在整個會議期間參加一對一的會議。
Key details about Dr. Magrath's presentation at the Aegis Capital Virtual Conference are below:
有關馬格拉斯博士在宙斯資本虛擬會議上的演講的關鍵細節如下：
Aegis Capital Virtual Conference – May 7-9, 2024
Aegis Capital 虛擬會議 — 2024 年 5 月 7-9 日
| Title of Presentation: | Ocuphire Pharma, Inc. (OCUP) Company Presentation |
| Presenter: | George Magrath, M.D. M.B.A, M.S. |
| Date: | Wednesday, May 8, 2024 |
| Time: | 3:00 – 3:25pm ET |
| 演示文稿標題： | Ocuphire Pharma, Inc. (OCUP) 公司介紹 |
| 演示者： | George Magrath，醫學博士，工商管理碩士 |
| 日期： | 2024年5月8日，星期三 |
| 時間： | 美國東部時間下午 3:00 — 3:25 |
If you are interested in arranging a one-on-one meeting, please contact your conference representative or send an email to [email protected]. For more details, please see the Investors and Events section of Ocuphire's corporate website.
如果您有興趣安排一對一的會議，請聯繫您的會議代表或發送電子郵件至 [電子郵件保護]。欲了解更多詳情，請參閱 Ocuphire 公司網站的 “投資者與活動” 部分。
About Ocuphire Pharma
關於 Ocuphire Pharma
Ocuphire is a clinical-stage ophthalmic biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders.
Ocuphire是一家臨床階段的眼科生物製藥公司，專注於開發治療視網膜和屈光眼病的新療法。
Ocuphire's lead retinal product candidate, APX3330, is an oral small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein) for the treatment of non-proliferative diabetic retinopathy (NPDR). Ref-1 is a regulator of the transcription factors HIF-1α and NF-κB. Inhibiting REF-1 reduces levels of vascular endothelial growth factor (VEGF) and inflammatory cytokines which are known to play key roles in ocular angiogenesis and inflammation. APX3330 is an oral tablet to be administered twice per day for the treatment of diabetic retinopathy (DR). A Phase 2 study in subjects with DR and an End-of-Phase 2 meeting have been completed, and a special protocol assessment (SPA) was submitted to the U.S. Food and Drug Administration ("FDA") in February 2024.
Ocuphire 的主要視網膜候選產品 APX3330 是一種口服小分子抑制劑 Ref-1（還原氧化效應因子-1 蛋白），用於治療非增殖性糖尿病視網膜病變（NPDR）。Ref-1 是轉錄因子 HIF-1α 和 NF-ωB 的調節劑。抑制 REF-1 可降低血管內皮生長因子 (VEGF) 和炎症細胞因子的水平，已知這些因子在眼部血管生成和炎症中起關鍵作用。APX3330 是一種口服片劑，每天服用兩次，用於治療糖尿病視網膜病變（DR）。一項針對DR受試者的2期研究和第二階段結束的會議已經完成，特別協議評估（SPA）已於2024年2月提交給美國食品藥品監督管理局（“FDA”）。
In addition, Ocuphire has a partnership with Viatris, Inc. to develop and commercialize Phentolamine Ophthalmic Solution 0.75% (PS), a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size. PS was approved by the FDA for the treatment for pharmacologically-induced mydriasis under the brand name RYZUMVI in September 2023. As discussed above, PS is also in Phase 3 clinical development for the treatment of presbyopia and for the treatment of decreased visual acuity under low light (mesopic) conditions after keratorefractive surgery.
此外，Ocuphire與Viatris, Inc.合作開發和商業化0.75％酚妥拉明眼科溶液（PS），這是一種非選擇性的α-1和α-2腎上腺素拮抗劑，旨在縮小學生體積。2023 年 9 月，PS 獲得 FDA 批准，用於治療藥理誘發的散大，品牌名稱爲 RYZUMVI。如上所述，PS也處於3期臨床開發階段，用於治療老花眼和治療角膜屈光手術後弱光（中視）條件下的視力下降。
Ocuphire is also developing APX2009 and APX2014, second-generation analogs of APX3330. These programs are being evaluated for treating other retinal diseases such as age-related macular degeneration and geographic atrophy. For more information, please visit www.ocuphire.com.
Ocuphire 還在開發 APX3330 的第二代類似物 APX2009 和 APX2014。正在評估這些計劃以治療其他視網膜疾病，例如與年齡相關的黃斑變性和地理萎縮。欲了解更多信息，請訪問 www.ocuphire.com。
Contacts
聯繫人
| Corporate | Investor Relations | |
| Nirav Jhaveri, MBA CFO [email protected] | Corey Davis, Ph.D. LifeSci Advisors [email protected] |
Released May 3, 2024
2024 年 5 月 3 日發佈
譯文內容由第三人軟體翻譯。